AVCN
vs
S
S&P TSX Composite Index (Canada)
AVCN
Over the past 12 months, AVCN has underperformed S&P TSX Composite Index (Canada), delivering a return of -30% compared to the S&P TSX Composite Index (Canada)'s +28% growth.
Stocks Performance
AVCN vs S&P TSX Composite Index (Canada)
Performance Gap
AVCN vs S&P TSX Composite Index (Canada)
Performance By Year
AVCN vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Avicanna Inc
Glance View
Avicanna, Inc. is a medical cannabis company, which intends to engage in the business of discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2019-07-18. The firm is engaged in cannabinoid research, development, and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. The firm's scientific platform commercializes over twenty products across four market segments: Medical Cannabis & Wellness Products, CBD Derma-Cosmetic Products, Pharmaceuticals and Cannabis Raw Materials, Seeds, and Bulk Formulations. Its Medical Cannabis & Wellness Products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of cannabidiol (CBD) and tetrahydrocannabinol (THC), marketed under the RHO Phyto brand. Its CBD Derma-Cosmetic Products are marketed under the Pura H&W or Pura Earth brands. Its cannabinoid-based drug candidates provide solutions for unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
